Coding-Complete Genome Sequences of 40 SARS-CoV-2 Omicron XBB, XBB.1, and XBB.2 Sublineage Strains in Bangladesh

被引：2

作者：

Habib, Mohammad Tanbir ^{[1
]}

Afrad, Mokibul Hassan ^{[2
]}

Rahman, Saikt ^{[1
]}

Khan, Manjur Hossain ^{[3
]}

Hossain, Mohammad Moajjam ^{[1
,4
]}

Khanam, Farhana ^{[2
]}

Thomson, Nicholas R. ^{[5
,6
]}

Shirin, Tahmina ^{[3
]}

Qadri, Firdausi ^{[1
,2
]}

机构：

[1] Inst Developing Sci & Hlth Initiat, Dhaka, Bangladesh

[2] Int Ctr Diarrhoeal Dis Res, Dhaka, Bangladesh

[3] Inst Epidemiol Dis Control & Res, Dhaka, Bangladesh

[4] Univ Dhaka, Dept Biochem & Mol Biol, Dhaka, Bangladesh

[5] Wellcome Sanger Inst, Wellcome Genome Campus, Hinxton, Cambs, England

[6] London Sch Hyg & Trop Med, London, England

来源：

MICROBIOLOGY RESOURCE ANNOUNCEMENTS | 2023年 / 12卷 / 03期

基金：

英国惠康基金;

关键词：

D O I：

10.1128/mra.00001-23

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Here, we report the coding-complete genome sequences of 40 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains of the newly emerged recombinant Omicron variants XBB, XBB.1, and XBB.2. The strains were isolated from nasopharyngeal swab samples that had been collected from symptomatic patients in Bangladesh between September and October 2022 and were sequenced using an Oxford Nanopore Technologies (ONT) system. Here, we report the coding-complete genome sequences of 40 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains of the newly emerged recombinant Omicron variants XBB, XBB.1, and XBB.2. The strains were isolated from nasopharyngeal swab samples that had been collected from symptomatic patients in Bangladesh between September and October 2022 and were sequenced using an Oxford Nanopore Technologies (ONT) system.

引用

页数：3

共 50 条

[41] SARS-CoV-2 XBB.1.16 variant: India in focus?
Varghese, Ryan
Pai, Sanidhya
Kumar, Dileep
Sharma, Rohit
JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (05)
[42] Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant
Uriu, Keiya
Ito, Jumpei
Zahradnik, Jiri
Fujita, Shigeru
Kosugi, Yusuke
Schreiber, Gideon
Sato, Kei
LANCET INFECTIOUS DISEASES, 2023, 23 (03): : 280 - 281
[43] Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024
Huiberts, Anne J.
Hoeve, Christina E.
de Gier, Brechje
Cremer, Jeroen
van der Veer, Bas
de Melker, Hester E.
van de Wijgert, Janneke H. H. M.
van den Hof, Susan
Eggink, Dirk
Knoll, Mirjam J.
EUROSURVEILLANCE, 2024, 29 (10)
[44] Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections
Chemaitelly, Hiam
Ayoub, Houssein H.
AlMukdad, Sawsan
Faust, Jeremy S.
Tang, Patrick
Coyle, Peter
Yassine, Hadi M.
Al Thani, Asmaa A.
Al-Khatib, Hebah A.
Hasan, Mohammad R.
Al-Kanaani, Zaina
Al-Kuwari, Einas
Jeremijenko, Andrew
Kaleeckal, Anvar H.
Latif, Ali N.
Shaik, Riyazuddin M.
Abdul-Rahim, Hanan F.
Nasrallah, Gheyath K.
Al-Kuwari, Mohamed G.
Butt, Adeel A.
Al-Romaihi, Hamad E.
Al-Thani, Mohamed H.
Al-Khal, Abdullatif
Bertollini, Roberto
Abu-Raddad, Laith J.
JOURNAL OF TRAVEL MEDICINE, 2023, 30 (05)
[45] Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants
Tamura, Tomokazu
Ito, Jumpei
Uriu, Keiya
Zahradnik, Jiri
Kida, Izumi
Anraku, Yuki
Nasser, Hesham
Shofa, Maya
Oda, Yoshitaka
Lytras, Spyros
Nao, Naganori
Itakura, Yukari
Deguchi, Sayaka
Suzuki, Rigel
Wang, Lei
Begum, M. S. T. Monira
Kita, Shunsuke
Yajima, Hisano
Sasaki, Jiei
Sasaki-Tabata, Kaori
Shimizu, Ryo
Tsuda, Masumi
Kosugi, Yusuke
Fujita, Shigeru
Pan, Lin
Sauter, Daniel
Yoshimatsu, Kumiko
Suzuki, Saori
Asakura, Hiroyuki
Nagashima, Mami
Sadamasu, Kenji
Yoshimura, Kazuhisa
Yamamoto, Yuki
Nagamoto, Tetsuharu
Schreiber, Gideon
Maenaka, Katsumi
Hashiguchi, Takao
Ikeda, Terumasa
Fukuhara, Takasuke
Saito, Akatsuki
Tanaka, Shinya
Matsuno, Keita
Takayama, Kazuo
Sato, Kei
NATURE COMMUNICATIONS, 2023, 14 (01)
[46] XBB.1, BQ1.1 and atypical BA.4.6/XBB.1 recombinants predominate current SARS-CoV-2 Wavelets with flu-like symptoms in Cameroon: A snapshot from genomic surveillance
Fokam, Joseph
Semengue, Ezechiel Ngoufack Jagni
Anguechia, Davy-Hyacinthe Gouissi
Etame, Naomi-Karell
Takou, Desire
Mandeng, Nadia
Ngueko, Minelle Aurelie Kengni
Angong, Grace Beloumou
Ndjeyep, Sandrine Djupsa
Ambe, Collins Chenwi
Nka, Alex Durand
Molimbou, Evariste
Nayang, Audrey Rachel Mundo
Fotso, Larissa Gaelle Moko
Ngwese, Derrick Tambe Ayuk
Tueguem, Pamela Patricia
Tchouaket, Carlos Michel Tommo
Ka'e, Aude Christelle
Fainguem, Nadine
Abega, Cyrille Abega
Halle-Ekane, Edie-Gregory
Esso, Linda
Mballa, Alain Georges Etoundi
Shang, Judith
Ndongmo, Clement B.
Cappelli, Giulia
Tessema, Sofonias Kifle
Bissek, Anne-Cecile Z-K
Colizzi, Vittorio
Ndjolo, Alexis
Perno, Carlo-Federico
Ndembi, Nicaise
PLOS GLOBAL PUBLIC HEALTH, 2024, 4 (05):
[47] XBB.1.5 Kraken cracked: Gibbs energies of binding and biosynthesis of the XBB.1.5 variant of SARS-CoV-2
Popovic, Marko E.
MICROBIOLOGICAL RESEARCH, 2023, 270
[48] Vaccination with ancestral SARS-CoV-2 spike adjuvanted with TLR agonists provides cross-protection against XBB.1
Stephanie K. Lathrop
Jordan J. Clark
Karthik Siram
Robert Andreata-Santos
Jeremy Yong
Rebekah D. Tee
Clara J. Davison
Gagandeep Singh
David Burkhart
Florian Krammer
Jay T. Evans
npj Viruses, 2 (1):
[49] Emergence and dissemination of SARS-CoV-2 XBB.1.5 in New York
Gambaro, Fabiana
Duerr, Ralf
Dimartino, Dacia
Marier, Christian
Iturrate, Eduardo
Mulligan, Mark J.
Heguy, Adriana
Dellicour, Simon
VIRUS EVOLUTION, 2024, 10 (01)
[50] Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals
Kosugi, Yusuke
Kaku, Yu
Hinay, Alfredo A., Jr.
Guo, Ziyi
Uriu, Keiya
Kihara, Minoru
Saito, Fumitake
Uwamino, Yoshifumi
Kuramochi, Jin
Shirakawa, Kotaro
Takaori-Kondo, Akifumi
Sato, Kei
LANCET INFECTIOUS DISEASES, 2024, 24 (03): : e147 - e148

← 1 2 3 4 5 →